Apellis Pharmaceuticals Reports 133% Revenue Growth and $215.7 Million Net Income for Q3 2025

Apellis Pharmaceuticals, Inc. reported significant financial performance in its latest 10-Q filing for the quarter ending September 30, 2025, showcasing a total revenue of $458.6 million, a substantial increase of 133% compared to $196.8 million in the same period last year. This growth was primarily driven by a remarkable rise in licensing and other revenue, which surged to $280.8 million from $20.3 million, largely due to a $275 million upfront payment from a Royalty Buy-Down Agreement with Swedish Orphan Biovitrum AB (Sobi). Product revenue from EMPAVELI and SYFOVRE remained stable, with EMPAVELI generating $26.8 million and SYFOVRE contributing $150.9 million in net product revenue.

In terms of profitability, Apellis reported a net income of $215.7 million for the third quarter of 2025, a significant turnaround from a net loss of $57.4 million in the same quarter of 2024. This improvement reflects a net operating income of $223.2 million, compared to a loss of $47.3 million in the prior year. The company also noted a decrease in total operating expenses, which fell to $235.4 million from $244.1 million, driven by lower research and development costs and a reduction in cost of sales.

Operationally, Apellis has made strides in expanding its product offerings and market presence. The FDA approved EMPAVELI for additional indications, including C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, in July 2025. The company is also focusing on the commercialization of SYFOVRE, which was launched in March 2023, and is exploring international expansion opportunities, including in Australia. As of September 30, 2025, Apellis reported an increase in accounts receivable to $345.5 million, reflecting strong sales performance.

The company’s strategic developments include the Royalty Buy-Down Agreement with Sobi, which significantly altered the revenue landscape by reducing Sobi's royalty obligations by 90% in exchange for the upfront payment. Additionally, Apellis is advancing its clinical pipeline, with plans to initiate pivotal trials for EMPAVELI by the end of 2025. The company also reported a headcount of 1,200 employees, reflecting its growth and expansion efforts.

Looking ahead, Apellis anticipates continued investment in commercialization and research activities, with expectations of incurring significant expenses related to the ongoing development of its product candidates. The company believes that its current cash and cash equivalents, totaling $479.2 million as of September 30, 2025, along with anticipated revenues from EMPAVELI and SYFOVRE, will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the inherent risks and uncertainties in the biotechnology sector, which may impact its future financial performance and operational plans.